Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The DLC-1 tumor suppressor is involved in regulating immunomodulation of human mesenchymal stromal /stem cells through interacting with the Notch1 protein

Fig. 4

The DLC-1’s inhibitory effect on the immunomodulation of hUC-MSCs is both RhoGAP domain-dependent and RhoGAP domain-independent. a The schemes of all DLC-1 mutants used in this study are presented. b In the co-transfection of pIDO-1-Luc with the cDNA of wild type DLC-1 (wtDLC-1) or its mutants in hUC-MSCs, the wtDLC-1 showed an approximately 50 % reduction of the IFN-γ-induced IDO1 promoter activity, while all mutants exhibited either no effect (DLC-1-662) or even enhanced effect (DLC-1-662, −Δ662, −R714E and DLC-1/RhoGAP), on the promoter activity. c Western bloting showed in the transfection studies that the cDNA of wtDLC-1, DLC-1-662, or DLC-Δ662 caused a significant reduction in IDO1 expression, while the cDNA of DLC-1/RhoGAP showed no effect on, and the cDNA of DLC-1/RhoGAP resulted in, a slight increase in the IDO1 expression

Back to article page
\